» Articles » PMID: 17308732

Progression to WHO Criteria for Antiretroviral Therapy in a 7-year Cohort of Adult HIV-1 Seroconverters in Abidjan, Côte D'Ivoire

Overview
Specialty Public Health
Date 2007 Feb 20
PMID 17308732
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To estimate the probability of reaching the criteria for starting highly active antiretroviral therapy (HAART) in a prospective cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire.

Methods: We recruited participants from HIV-positive donors at the blood bank of Abidjan for whom the delay since the estimated date of seroconversion (midpoint between last negative and first positive HIV-1 test) was < 36 months. Participants were offered early trimethoprim-sulfamethoxazole (cotrimoxazole) prophylaxis, twice-yearly measurement of CD4 count and we made standardized records of morbidity. We used the Kaplan-Meier method to estimate the probability of reaching the criteria for starting HAART according to WHO 2006 guidelines.

Findings: 217 adults (77 women (35%)) were followed up during 668 person-years (PY). The most frequent diseases recorded were mild bacterial diseases (6.0 per 100 PY), malaria (3.6/100 PY), herpes zoster (3.4/100 PY), severe bacterial diseases (3.1/100 PY) and tuberculosis (2.1/100 PY). The probability of reaching the WHO 2006 criteria for HAART initiation was estimated at 0.09, 0.16, 0.24, 0.36 and 0.44 at 1, 2, 3, 4 and 5 years, respectively.

Conclusion: Our data underline the incidence of the early HIV morbidity in an Ivorian adult population and provide support for HIV testing to be made more readily available and for early follow-up of HIV-infected adults in West Africa.

Citing Articles

Clinical Benefits and Cost-Effectiveness of Laboratory Monitoring Strategies to Guide Antiretroviral Treatment Switching in India.

Freedberg K, Kumarasamy N, Borre E, Ross E, Mayer K, Losina E AIDS Res Hum Retroviruses. 2018; 34(6):486-497.

PMID: 29620932 PMC: 5994680. DOI: 10.1089/AID.2017.0258.


New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon.

Ndawinz J, Anglaret X, Delaporte E, Koulla-Shiro S, Gabillard D, Minga A Bull World Health Organ. 2015; 93(8):521-8.

PMID: 26478609 PMC: 4581657. DOI: 10.2471/BLT.14.147892.


Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability.

Kimmel A, Resch S, Anglaret X, Daniels N, Goldie S, Danel C Cost Eff Resour Alloc. 2012; 10(1):12.

PMID: 22992315 PMC: 3502124. DOI: 10.1186/1478-7547-10-12.


Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis.

Anglaret X, Scott C, Walensky R, Ouattara E, Losina E, Moh R Antivir Ther. 2012; 18(1):45-55.

PMID: 22809695 PMC: 3893045. DOI: 10.3851/IMP2231.


The cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysis.

Pho M, Swaminathan S, Kumarasamy N, Losina E, Ponnuraja C, Uhler L PLoS One. 2012; 7(4):e36001.

PMID: 22558301 PMC: 3340407. DOI: 10.1371/journal.pone.0036001.


References
1.
Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B . Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS. 2003; 17 Suppl 3:S5-15. DOI: 10.1097/00002030-200317003-00002. View

2.
Morgan D, Mahe C, Mayanja B, Okongo J, Lubega R, Whitworth J . HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries?. AIDS. 2002; 16(4):597-603. DOI: 10.1097/00002030-200203080-00011. View

3.
. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted.... Lancet. 2000; 355(9210):1131-7. View

4.
Morgan D, Mahe C, Mayanja B, Whitworth J . Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study. BMJ. 2002; 324(7331):193-6. PMC: 64788. DOI: 10.1136/bmj.324.7331.193. View

5.
Rangsin R, Chiu J, Khamboonruang C, Sirisopana N, Eiumtrakul S, Brown A . The natural history of HIV-1 infection in young Thai men after seroconversion. J Acquir Immune Defic Syndr. 2004; 36(1):622-9. DOI: 10.1097/00126334-200405010-00011. View